Document is current
Any future updates will be listed below
-
Authors
Vacurova, Eliska http://orcid.org/0000-0002-7173-4189
Trnovska, Jaroslava
Svoboda, Petr http://orcid.org/0000-0001-7297-4208
Skop, Vojtech http://orcid.org/0000-0002-4685-4429
Novosadova, Vendula
Reguera, David Pajuelo http://orcid.org/0000-0002-7715-9402
Petrezselyová, Silvia http://orcid.org/0000-0003-3054-540X
Piavaux, Benoit
Endaya, Berwini
Spoutil, Frantisek
Zudova, Dagmar
Stursa, Jan
Melcova, Magdalena http://orcid.org/0000-0002-0054-6113
Bielcikova, Zuzana http://orcid.org/0000-0001-8434-9848
Werner, Lukas
Prochazka, Jan
Sedlacek, Radislav http://orcid.org/0000-0002-3352-392X
Huttl, Martina
Hubackova, Sona Stemberkova http://orcid.org/0000-0002-3454-6840
Haluzik, Martin http://orcid.org/0000-0002-0201-6888
Neuzil, Jiri http://orcid.org/0000-0002-2478-2460
- License Information
-
More Information
Article History
Received: 25 August 2020
Accepted: 17 March 2022
First Online: 6 April 2022
Competing interests
: S.S.H., J.N., J.S., and L.W. are co-inventors of MitoTam as a senolytic agent, and J.N., J.S., and L.W. are co-owners of MitoTax s.r.o. and the MitoTam intellectual property, together with KKCG a.s. and SmartBrain s.r.o., who financed the MitoTam-01 oncolytic trial. Other authors declare no conflict of interest.
